首页> 美国卫生研究院文献>NPG Open Access >Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

【2h】

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

机译：高危MDS或AML患者异基因干细胞移植后脱乙酰酶抑制剂panobinostat的I / II期研究（PANOBEST试验）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 NPG Open Access
作者
G Bug; A Burchert; E-M Wagner; N Kröger; T Berg; S Güller; S K Metzelder; A Wolf; S Hünecke; P Bader; J Schetelig; H Serve; O G Ottmann;
展开▼
作者单位

展开▼
年(卷),期 -1(31),11
年度 -1
页码 2523–2525
总页数 3
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT) [J] . Cornelissen Jan J., van Norden Yvette, van Gelder Michel, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Panobinostat和地西他滨的早期移植后表观遗传治疗，随后进行供体淋巴细胞输注（DLI）：同种异体干细胞移植（alloHSCT）的低风险AML接受者中HOVON-116 I / II期可行性研究的中期结果
2. Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat [J] . Pagel John M., Othus Megan, Garcia-Manero Guillermo, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：高风险AML患者首次完全缓解后进行异基因造血细胞移植的可行性：SWOG（S1203）随机移植III期目标的结果，采用标准7 + 3疗法或依达比星联合大剂量阿糖胞苷（IA）进行诱导疗法）与IA Plus Vorinostat对比
3. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma [J] . Chen Yi-Bin, Li Shuli, Fisher David C., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第9期

机译：串联高剂量化疗的II期试验用自体干细胞移植，随后对高风险淋巴瘤患者的强度异构性干细胞移植
4. Circulating Tumor DNA Predicts Post-Allogeneic Hematopoietic Stem Cell Transplantation in AML and MDS [C] . Sousuke Nakamura International Molecular Medicine Tri-Conference. . 2019

机译：循环肿瘤DNA预测AML和MDS中的同种异体造血干细胞移植
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial [O] . Kenichi Yamahara, Akiko Hamada, Toshihiro Soma, 2019

机译：异体造血干细胞移植后类固醇难治性急性移植物抗宿主病患者中羊膜来源间充质干细胞（AM01）的安全性和有效性：一项I / II期日本试验的研究方案
7. Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL [O] . Chen Yi-Bin, Li Shuli, Del Rio Candice, 2014

机译：AML，MDS和ALL患者同种异体造血干细胞移植降低强度的丁硫丹/氯法拉滨调理的II期试验

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

著录项

引文网络

相似文献

相关主题

期刊订阅